Skip to main content

Connecting Healthcare Professionals to Scientific Information

UCBCOMPASS® provides scientific education and
medical information on UCB medicines used to treat
certain immune-mediated inflammatory conditions
and rare diseases.

 

Search Congress Materials
Announcements

 

RHEUMATOLOGY

BIMZELX® (bimekizumab-bkzx) is now FDA approved for the treatment of adults with active PsA, nr-axSpA, and AS. See the phase 3 clinical trial data in Publications.

 

DERMATOLOGY

BIMZELX® (bimekizumab-bkzx) is now FDA approved for the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS). See the phase 3 clinical trial data in Publications.

 

 

UCB continues to proactively monitor the COVID-19 situation. To learn more about UCB's preparedness, click here.

 

RHEUMATOLOGY

The Women's Health Fellowship Program application is now closed. Learn More

Listen to Podcasts

Gain insights as scientists, medical experts, and patients discuss advances and unmet needs in inflammatory autoimmune conditions.

/disease-education/scientific-education-podcasts
Find Publications

Review the latest UCB research, including original articles, from peer-reviewed sources.

/our-science/publications
Opportunities for Investigators

Submit a study concept, request access to patient-level data from UCB trials, or become a UCB clinical trial investigator.

/our-science/research-support